RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Cannabics Pharmaceuticals Stock

Cannabics Pharmaceuticals ROE 2024

Cannabics Pharmaceuticals ROE

1.84

Ticker

CNBX

ISIN

US13764M1009

WKN

A116WM

In 2024, Cannabics Pharmaceuticals's return on equity (ROE) was 1.84, a -19.52% increase from the 2.28 ROE in the previous year.

Cannabics Pharmaceuticals Aktienanalyse

What does Cannabics Pharmaceuticals do?

Cannabics Pharmaceuticals Inc. is a global company that specializes in the development of personalized therapies using medical cannabis. The company was founded in Israel in 2010 and is headquartered in Tel Aviv. Since then, the company has become a leading player in the medical cannabis industry and has expanded to the United States and Europe. The company's history began with a groundbreaking discovery by the founder's team, who found a method for isolating cannabinoids from cannabis and discovered that cannabinoids have the potential to kill tumor cells. This discovery became the company's passion and they began to focus on the production of personalized therapies using medical cannabis. Cannabics' business model consists of three main divisions: research and development, manufacturing, and commercial distribution of medical cannabis. The company is able to develop personalized therapies that take into account the specific needs of each patient by following a comprehensive approach that considers the specific needs of each patient. Cannabics' research and development department focuses on the development of new personalized therapies and medical devices that include cannabis components. This includes clinical studies to demonstrate the efficacy and safety of cannabis-based medications. The company also works closely with renowned research and development institutions to leverage the latest research and technology. The manufacturing of medical cannabis is another important division of Cannabics. The company operates as a supplier, producing high-quality, personalized cannabis oil specifically tailored to meet the patient's needs. Cannabics works with various strains and cannabis extracts to ensure that each formulation contributes to symptom relief and is safe and effective. Commercial distribution is the third pillar of Cannabics' business model. The company aims to provide its personalized therapies through pharmacies and direct distribution channels to ensure that they reach patients worldwide. Cannabics offers a variety of products, including personalized doses of medical cannabis oil, specific terpene profiles, capsules, extracts, and orally administered medications. The company also offers cannabis tests that are specifically tailored for profiling cancer cells and enabling specific personalization. In recent years, the company has focused on the development of personalized therapies for the treatment of cancer. One of its notable developments is the "Cannabics SR" platform, which provides personalized treatment options for each individual patient based on their cancer genetics. The platform consists of a diagnostic tool to determine the patient's individual cancer and tumor profile. Based on these analyses, the company then formulates a tailored medical treatment using different cannabinoids. Overall, Cannabics Pharmaceuticals Inc. has become a leading company in the medical cannabis industry. The company places a strong emphasis on research and development to develop personalized therapies for the treatment of cancer and other medical conditions and to distribute them worldwide. Cannabics Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Cannabics Pharmaceuticals's Return on Equity (ROE)

Cannabics Pharmaceuticals's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Cannabics Pharmaceuticals's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Cannabics Pharmaceuticals's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Cannabics Pharmaceuticals’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Cannabics Pharmaceuticals stock

What is the ROE (Return on Equity) of Cannabics Pharmaceuticals this year?

The ROE of Cannabics Pharmaceuticals this year is 1.84 undefined.

How has the Return on Equity (ROE) of Cannabics Pharmaceuticals developed compared to the previous year?

The ROE of Cannabics Pharmaceuticals has increased by -19.52% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Cannabics Pharmaceuticals?

A high ROE indicates that Cannabics Pharmaceuticals generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Cannabics Pharmaceuticals?

A low ROE can indicate that Cannabics Pharmaceuticals is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Cannabics Pharmaceuticals affect the company?

A change in ROE (Return on Equity) of Cannabics Pharmaceuticals can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Cannabics Pharmaceuticals?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Cannabics Pharmaceuticals?

Some factors that can influence Cannabics Pharmaceuticals's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Cannabics Pharmaceuticals pay?

Over the past 12 months, Cannabics Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Cannabics Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Cannabics Pharmaceuticals?

The current dividend yield of Cannabics Pharmaceuticals is .

When does Cannabics Pharmaceuticals pay dividends?

Cannabics Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Cannabics Pharmaceuticals?

Cannabics Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Cannabics Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Cannabics Pharmaceuticals located?

Cannabics Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Cannabics Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Cannabics Pharmaceuticals from 10/8/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/8/2024.

When did Cannabics Pharmaceuticals pay the last dividend?

The last dividend was paid out on 10/8/2024.

What was the dividend of Cannabics Pharmaceuticals in the year 2023?

In the year 2023, Cannabics Pharmaceuticals distributed 0 USD as dividends.

In which currency does Cannabics Pharmaceuticals pay out the dividend?

The dividends of Cannabics Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Cannabics Pharmaceuticals

Our stock analysis for Cannabics Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Cannabics Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.